ECOR · electroCore, Inc.
$9.97
+0.03 (+0.30%)
At close · Aug 14
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Notwithstanding the expected cash flow from operations and expected access to capital from existing and/or future debt and equity sources, the Company’s currently forecasted cash is less than the requirements to fund its operating expenses and capital expenditure requirements, as currently planned, for at least the next 12 months from the date the accompanying condensed consolidated financial statements are issued. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$89.89M
Shares
9.02M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.97
Open$9.71
Day$9.68–10.39
52W close$4.42–10.35
Avg vol 30d90K
Short int351K · 3.9% float · 7.6d
Short vol53%
Last earningsAug 6, 2026
DataFeb 2023–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on Feb 15, 2023; bars on opposite sides are not compared.
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+53%
above
Price vs 50-day avg
+29%
above
RSI (14)
78
overbought
MACD trend
Positive
52-week position
94%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+70%
trailing
6-month return
+50%
trailing
YTD return
+122%
this year
Relative strength
+36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +8 funds added
Insider flow
Distributing
Net -$19.7K over 90 days · 50% sells
Short interest
Falling
3.89% of float · ▼ -4.6% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
32 holders — mid 3-yr range
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+27%
Y/Y
Gross margin
87%
expanding
EPS growth
−4%
Y/Y
Free cash flow
$-8.3M
Balance sheet
$116.4K
net cash
Quant / Vol
risk profile
Volatility
87%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Sales and marketing expense as a percentage of revenue
· by the end of 2027
54%
Prior guidance
period ended
· from the 8-K filed Jan 20, 2026
Revenue
· full year 2025
$31.8M – $32M
Revenue
· fourth quarter 2025
$9M – $9.2M
Cash, cash equivalents, and marketable securities ("Total Cash")
· as of December 31, 2025
$11.6M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+53%
Bullish
Price vs 50-day avg
+29%
Bullish
RSI (14)
78
Bearish
MACD trend
Positive
Bullish
52-week position
94%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +8 funds added
Insider flow
Distributing
Net -$19.7K over 90 days · 50% sells
Short interest
Falling
3.89% of float · ▼ -4.6% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
32 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $10 · 94%
Range high $10
vs 200-day avg +53%
vs 50-day avg +29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA net loss non-GAAP | $1.8M | the second quarter of 2026 | — |
| Adjusted EBITDA net loss improvement (year-over-year) non-GAAP | 26% | the second quarter of 2026 | — |
| Prescription (Rx) gammaCore revenue growth | 11% | the second quarter of 2026 | — |
| Quell product line sales | $1.3M | the second quarter of 2026 | — |
| Quell product line sales growth (sequential) | 30% | the second quarter of 2026 | — |
| Quell product line sales growth (year-over-year) | 700% | the second quarter of 2026 | — |
| Truvaga revenue | $1.3M | the second quarter of 2026 | — |
|
|
|||
| Truvaga revenue growth (year-over-year) | 27% | the second quarter of 2026 | — |
| VA headache market penetration | 2.7% | the second quarter of 2026 | — |
|
|
|||
| VA patients who have received a gammaCore device | 16,400 | the second quarter of 2026 | — |
|
|
|||
| Adjusted EBITDA net loss improvement non-GAAP | 24% | first quarter 2026 | — |
| Cumulative Quell Fibromyalgia revenue sold into the VA | $2.5M | first quarter 2026 | — |
| Cumulative Quell revenue since acquisition | $2.7M | first quarter 2026 | — |
| Gross profit margin | 87% | first quarter 2026 | — |
| Prescription gammaCore revenue growth | 26% | first quarter 2026 | — |
| Return on advertising spend (ROAS) | 2.37 | first quarter 2026 | — |
| ROAS sequential improvement | 14% | first quarter 2026 | — |
| Truvaga revenue growth | 38% | first quarter 2026 | — |
| VA facilities which have purchased prescription gammaCore products | 200 | first quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ECOR
this stock
electroCore, Inc.
|
$89.89M | +122.3% | +27.2% | — | 3.9% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Feb 15, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ECOR | +23.2% | +69.6% | +49.7% | +63.9% | +122.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +22.8% | +65.1% | +35.9% | +59.9% | +108.5% |
Key facts
CIK
1560258
CUSIP
28531P202
13F (30d)
34 filings
33 filers
Visit website
Investor relations